PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's
PD Frontline
PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
1 other identifier
observational
4,800
1 country
1
Brief Summary
PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 15, 2020
CompletedFirst Submitted
Initial submission to the registry
October 11, 2023
CompletedFirst Posted
Study publicly available on registry
November 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 20, 2040
ExpectedNovember 30, 2023
November 1, 2023
5 years
October 11, 2023
November 28, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Genotype of participants
The primary outcome of the study is to genotype the GBA1 gene, obtained with Oxford Nanopore long read sequencing.
20 years
Eligibility Criteria
Randomly selected population, recruited via established NHS sites and self-referral to the website.
You may qualify if:
- Formal diagnosis of Parkinson Disease
You may not qualify if:
- Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.
- History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)
- Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.
- Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University College London Hospitalslead
- Cure Parkinson'scollaborator
Study Sites (1)
University College London (UCL)
London, NW3 2PF, United Kingdom
Biospecimen
Extracted DNA from saliva samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 20 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor Anthony Schapira
Study Record Dates
First Submitted
October 11, 2023
First Posted
November 30, 2023
Study Start
February 15, 2020
Primary Completion
February 14, 2025
Study Completion (Estimated)
August 20, 2040
Last Updated
November 30, 2023
Record last verified: 2023-11